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patients. A typical PCU admits patients in the ﬁnal phase of life. A high quality of 
care by a multi disciplinary team (including nurses, physicians, psychologists, music 
therapy, physiotherapy and others) results in substantial costs (recent survey in 
German PCUs: on average ~a400/day). The average length of stay is in the range of 
11–15 days, the proportion of discharged patients varies between 40–70%, for the 
remaining patients the admission ends not unexpectedly with the death of the patients. 
The gain in utility close to death is difﬁcult to estimate, but even high assumptions 
(e.g. 0,5) result in costs for QALYs, which are unexpectedly high. Scenario 1: 14, 0.5, 
30, 0.5, 400, 192455 a; scenario 2: 14, 0.7,30, 0.5, 400, 172545 a; scenario 3: 14, 
0.5, 30, 0.3, 400, 320758 a; scenario 4: 10, 0.5, 30, 0.5, 400, 182500 a for length of 
stay (d), proportion surviving, survival after discharge (d), gain in utility, cost/day, 
resulting cost / QALY. People experiencing the sheer necessity of palliative care for a 
death with dignity may use these data as an argument against the QALY concept. 
Only by including longterm changes e.g. in the utility gain experienced by relatives 
(small gains over a long period in several persons, e.g. by avoiding pathological grief) 
the model results in costs/QALY which seem acceptable.
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OBJECTIVES: To evaluate treatment-related toxicities among patients with squamous 
cell carcinoma of the head and neck (SCCHN) treated in real-world clinical practices. 
METHODS: We used a population-based tumor registry at a large, US health system, 
to identify all cases of stage III or IV SCCHN diagnosed from 2000 to 2006. We 
identiﬁed the incidence/severity of acute and late toxicities associated with SCCHN 
treatment from detailed medical record reviews. Acute and late toxicities were evalu-
ated using CTCAE3 criteria and RTOG/EORTC late radiation morbidity scoring 
scheme, respectively. The incidence and severity of toxicities are presented by treat-
ments. Detailed analyses according to tumor stage and location, grade, and acute 
versus late events were examined. RESULTS: We identiﬁed 195 patients with SCCHN: 
A total of 104 patients (53%) received chemotherapy (chemo)  radiation therapy 
(RT); 87 (45%) received RT only; four patients (2%) received chemotherapy only or 
other/no treatment. Adverse Events of Interest (grade 2–4) by Treatment Received (N 
 191*): Gastrointestinal: 160 (83.8), 89 (85.6), 71 (81.6); Xerostomia: 61 (31.9), 41 
(39.4), 20 (23.0); Dysphagia: 70 (36.6), 44 (42.3), 26 (29.9); Dermatology: 91 (47.6), 
54 (51.9), 37 (42.5); Pulmonary: 74 (38.79), 41 (39.4), 33 (37.9); Aspiration pneu-
monia: 62 (32.5), 37 (35.6), 25 (28.7); Dehydration: 43 (22.5), 29 (27.9), 14 (16.1); 
Subcutaneous tissue: 30 (15.7), 18 (17.3), 12 (13.8); Infection: 29 (15.2), 21 (20.2), 
8 (9.2); Renal/Genitourinary: 19 (9.9), 14 (13.5), 5 (5.7); Auditory: 16 (8.4), 12 (11.5), 
4 (4.6); Bone: 4 (2.1), 3 (2.9), 1 (1.1) for Total n  191 n(%), ChemoRT n  104 
n(%), RT only n  87 n(%). Note: Four patients received chemotherapy only or 
other/no treatment. CONCLUSIONS: Treatment-related toxicity in patients with 
advanced SCCHN is common. The addition of chemotherapy to radiation is associ-
ated with increased risk treatment-related toxicities. These data provide real-world 
incidence rates of toxicity as observed in clinical practice.
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OBJECTIVES: The Dutch policy measure on expensive inpatient medicines aims to 
ensure accessibility by relieving ﬁnancial burden of hospitals. After three years, 
outcomes research inﬂuences decision-making on the continuation of additional 
funding. We explored the consequences of daily clinical practice variation for 
real-world pharmacoeconomics of bortezomib in relapsed or refractory multiple 
myeloma. METHODS: Our study included 139 multiple myeloma patients who 
progressed from ﬁrst line therapy and received bortezomib outside of an RCT. 
Detailed case reports were retrospectively collected from medical records in 38% of 
all Dutch hospitals. Treatment variation and combinations of bortezomib were 
explored until sixth line therapy. RESULTS: All patients had at least two treatment 
lines, 66% received third line, 41% fourth line, 14% ﬁfth line and 6% sixth line 
therapy. At least nine chemical agents were given in all lines as mono-therapy or in 
different combinations. No speciﬁc treatment order could be identiﬁed because of large 
variation in regimes and drug usage in different and reversed order. Moreover, guide-
lines have changed over the years and recommend earlier use of bortezomib; and 
lenalidomide, another very effective medicine, was increasingly used. In total, 72 
patients received bortezomib, 30% as mono-therapy and 70% as combination 
therapy. Bortezomib was most often combined with dexamethasone (60%), but com-
binations with ﬁve other drugs were seen. Clinical guidelines state that differences in 
patient circumstances require professional discretion; this results in extensive vari-
ability in daily practice. CONCLUSIONS: Compared to an RCT, outcomes research 
of bortezomib is complicated by extensive treatment variation in daily clinical practice. 
This suggests that a standard pharmacoeconomic model comparing two treatment 
arms is not sufﬁcient. Comprehensive modelling using different data sources is 
required to acquire a valid and precise (cost-) effectiveness measure of bortezomib in 
daily clinical practice.
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OBJECTIVES: Comparative effectiveness assessments require standardization of clini-
cal trial control arms to enable valid indirect comparisons. In order to inform guidelines 
on such adjustments, we provide insights on the Interferon-alpha-2a (IFN-A) control 
arm adjustment performed for comparing bevacizumab (BEV)  Interferon-alpha-2a 
(IFN-A) vs. sunitinib (SUN) in ﬁrst-line metastatic renal-cell cancer. METHODS: 
Adjustments were based on hazard ratios (HR) and median progression-free survival 
(PFS) time. Based on published phase-III trial investigator-assessed PFS (SUN vs. IFN-A 
HR 0.519; SUN PFS 10.8 months [m]; IFN-A 4.1m; BEVIFN-A vs. IFN-A HR 0.630; 
BEV PFS 10.2 m; IFN-A 5.4 m), indirect HRs were recalculated by adjusting IFN-A 
arms applying two scenarios: 1. IFN-A PFS of BEV  SUN IFN-A PFS (4.1 m); 
2. IFN-A PFS of SUN  BEV IFN-A PFS (5.4 m). Applying the cross-trial proportions 
of indirect HRs to direct HRs, the recalculated indirect HRs have been transferred to 
direct HR estimates (cross-trial rule of proportion approach). This approach was tested 
by adjusting the BEV trial IFN-A curve and recalculating the direct HR based on a 
Weibull model, applied to original phase III data. RESULTS: In scenario 1, the HR 
of SUN vs. IFN-A increased to 0.595; in scenario 2 the HR of BEVIFN-A decreased 
to 0.550. Indirect comparison results of SUN vs. BEVIFN-A where comparable for 
both scenarios (HR SUN vs. BEVIFN-A  0.945; CIs: 0.73–1.22; p-value  0.66). 
Testing scenario 2 based on a Weibull-function resulted in HR of BEV  IFN-A 
of 0.517. Applying an updated approach replicating the analysis results for scenario 
2 resulted in an indirect comparison HR of SUN vs. BEVIFN-A of 1.010 (CIs: 
0.79–1.30; p  0.94). CONCLUSIONS: As original trial data are often not accessible, 
using indirect HRs and adjusting them according to the method presented seems 
to be a practicable approach that could be performed based on published data.
PODIUM SESSION II: ECONOMIC EVALUATION AND REIMBURSEMENT 
DECISIONS I
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USING IQWIG’S EFFICIENCY FRONTIER APPROACH FOR THE 
ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT—A PILOT 
AND FEASIBILITY STUDY COMMISSIONED BY IQWIG
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OBJECTIVES: The German HTA agency IQWiG published new guidelines on health-
economic evaluations for the statutory health care system. The goals of this pilot study 
commissioned by IQWiG were: 1) to apply the efﬁciency frontier (EF) approach 
to evaluate the cost-effectiveness of combination therapy with peginterferon plus 
 ribavirin (PegIFN  RBV) in patients with chronic hepatitis C (CHC); and 2) to assess 
the feasibility of the EF approach in this case example. METHODS: IQWiG’s EF 
approach assesses the cost-effectiveness of the new treatment (i.e., PegIFN  RBV) 
within the speciﬁc disease area (i.e., CHC) by comparing the new treatment’s incre-
mental cost-effectiveness ratio (ICER) to ICERs of established treatments. We used a 
lifetime Markov model to determine health outcomes and costs of all treatment 
options. Health outcomes included sustained virological response (SVR), lifetime risk 
of decompensated cirrhosis and quality-adjusted life years (QALY). Model parameters 
were derived from the published literature and German databases. We adopted the 
perspective of citizens insured through the statutory health insurance. We performed 
a budget impact analysis reporting annual incremental costs. RESULTS: The ICERs 
of PegIFN  RBV compared to interferon plus ribavirin (IFN  RBV) were EUR 
15,000 EUR/SVR avoided, EUR 42,000/decompensated cirrhosis avoided, and EUR 
4,000/QALY. These ICERs are substantially lower than those of the last segments 
of the respective EFs (i.e., ICER of IFN  RBV vs. IFN monotherapy) indicating cost-
effectiveness of PegIFN  RBV. The expected incremental annual budget ranged 
between 15 and 134 million EUR. The introduction of new genotype-speciﬁc treat-
ment guidelines led to cost-savings when compared to IFN  RBV. CONCLUSIONS: 
PegIFN  RBV should be cost-effective compared to other established treatments in 
CHC. The EF approach should be feasible for HTAs in the CHC area. However, 
several issues remain to be solved and the conclusions derived from HTAs based on 
IQWiG’s framework may substantially differ from HTAs assuming uniform willing-
ness-to-pay thresholds across the entire health care system.
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OBJECTIVES: To get insight in what criteria as presented in HTA studies are impor-
tant for decision makers in health care priority setting. METHODS: We performed a 
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DCE among Dutch health care professionals (policymakers, HTA specialists, advanced 
HTA students). In 27 choice sets, we asked respondents to elect reimbursement of one 
of two different health care interventions, which represented unlabeled, curative treat-
ments. Both treatments were incrementally compared to usual care. The results of the 
interventions were normal outputs of HTA studies with a societal perspective. Results 
were analysed using a multinomial logistic regression model. Upon completion of the 
questionnaire we discussed the exercise with policymakers. RESULTS: Severity of 
disease, costs per QALY gained, individual health gain, and the budget impact were 
the most decisive decision criteria. A program targeting more severe diseases increased 
the probability of reimbursement dramatically. Uncertainty related to the cost-effec-
tiveness ratio was also important. Respondents preferred health gains that include 
quality of life improvements over extension of life without improved quality of life. 
Savings in productivity costs were not crucial in decision making, although these are 
to be included in Dutch reimbursement dossiers for new drugs. Regarding sub groups, 
we found that policymakers attached relatively more weight to disease severity than 
others but less to uncertainty. The DCE results indicated a willingness to pay of about 
a93,000 for a QALY. This meshes nicely with the recommendations of the Dutch 
Health Care Council. CONCLUSIONS: Dutch policymakers seem to have reasonably 
well articulated preferences: six of seven attributes were signiﬁcant. Disease severity, 
budget impact, and cost-effectiveness were very important. The results are comparable 
to international studies, but reveal a larger set of important decision criteria.
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OBJECTIVES: In contrast to the US, several European countries have health technol-
ogy assessment programs (HTA) for drugs, many of which assess cost-effectiveness. 
However, restricting access to pharmaceuticals is controversial, particularly for life-
threatening diseases. Therefore the objective of this study was to assess whether eco-
nomic evaluation as part of HTA restricts access to anticancer drugs. METHODS: 
We undertook a systematic comparison of US and UK coverage decisions on anticancer 
drugs taken by the US Centers for Medicare and Medicaid (CMS), the Veterans’ Affairs 
(VA), the Regence Group (US), the National Institute for Health and Clinical 
Excellence (NICE) (UK), and the Scottish Medicines Consortium (SMC) (UK). We 
noted the timing and outcome of coverage decisions made for all anticancer drugs 
approved by the Food and Drug Administration (FDA) between 2004 and 2008. 
RESULTS: Since 2004, the FDA has approved 51 anticancer drugs, of which 39 have 
been approved by the European Medicines Agency (EMEA). On average, the FDA 
licensed these drugs 127 days earlier than EMEA. The CMS and the VA covered 
all 51 drugs from the FDA license date. The Regence group also covered all 51 
drugs, although coverage decisions that considered cost-effectiveness sometimes took 
longer. Relative to the EMEA license date, coverage decisions for anticancer drugs by 
NICE averaged 774 days (SMC: 231 days). In the US, most drugs were available 
without clinical restriction, but NICE made positive coverage decisions for just 33% 
of licensed drugs (SMC: 51%). However, US patients face substantial copayments, 
whereas drugs are free for UK cancer patients. CONCLUSIONS: The use of economic 
evaluation does lead to more restrictions on the use of anticancer drugs. However, 
the major difference between the UK and US is not whether there are restrictions on 
access to anticancer drugs, but how these are applied and who bears the decision-
making burden.
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BACKGROUND: HTA has become the key tool to control market access for new 
technologies in Europe. This development has been mirrored in Germany through 
institutions such as DIMDI and, later, IQWiG at federal level, paralleled by similar 
tools at sickfund level. Furthermore, bilateral market access agreements appear to 
bloom. OBJECTIVES: To explore the foundation and trends of future health care 
decision-making in Germany. To formulate recommendations to manufacturers 
seeking market access for new technologies in Germany with respect to a number of 
key launch parameters. METHODS: We reviewed the development of allocative deci-
sion-making in Germany with particular attention to IQWiG (methods, international 
collaboration, decisions to date, impact). Furthermore, the role of other routes was 
examined (EVITA, rebate contracts, risk-sharing). RESULTS: IQWiG assessments 
have had a crucial impact on some products, e.g. clopidogrel and the fast-acting insulin 
analogues, and other manufacturers can learn from these decisions. While IQWiG will 
most likely cooperate with NICE and HAS on a number of issues such as evidence 
synthesis, a harmonized set of methods, leave alone decisions, cannot be expected in 
the near future. The future signiﬁcance of other access routes still needs to be deter-
mined. CONCLUSIONS: Manufacturers must be prepared for IQWiG assessments 
to be used for pricing purposes. Evidence must stem from randomized controlled 
trials wherever possible. Cost-effectiveness analysis will remain a second step of the 
appraisal, to which a new technology will only be admitted after having overcome a 
stand-alone effectiveness assessment. Neither QALYs nor a cost-per-QALY threshold 
will be used for decision-making. Germany will continue to grant high rewards to 
innovation, but careful thought must be given by manufacturers on how to present 
the added value of such innovations—be it via the IQWiG, a potential EVITA, or a 
direct contracting route.
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OBJECTIVE: Elderly (65y) are steadily growing, but this population segment is also 
the one in whom mortality, morbidity and health care costs increase sharply with age 
as a result of co-morbidity and greater frailty. This project intends to document the 
implications of using different modelling approaches on the beneﬁt evaluation of a 
public health intervention in elderly. METHODS: We designed a mathematical model 
to simulate the effect of a hypothetical public health intervention aiming at reducing 
mortality in the 65 y. The simulation is run on an elderly population of 1,000,000 
individuals (age weighted average of 75.66 y). The impact of the intervention is com-
pared between a cohort model (i.e., average parameters applied to the 75.66 year- old 
elderly cohort) and a population model (i.e., age-speciﬁc parameters applied to the 
entire elderly population). Life-expectancy gains (LEG) from both approaches were 
computed between intervention and no-intervention. Various scenarios were com-
pared through a range of different mathematical speciﬁcations of age-speciﬁc inter-
vention coverage and mortality reduction. RESULTS: In the cohort approach, life 
expectancies were respectively 11.38 and 11.48 years between no-intervention and 
intervention, i.e. a LEG of 0.10 y for the 75.66 y-old elderly cohort. In the population 
approach, age-speciﬁc life expectancies averaged 11.51 and 12.19 y between no-
 intervention and intervention, respectively. This translated into a weighted average 
LEG of 0.52 y, i.e. a gain 5-times higher than in the cohort approach. This result was 
conﬁrmed in various scenarios. CONCLUSION: Population modelling, whilst being 
potentially more data-hungry and mathematically demanding, allows for more com-
prehensive consideration of age-speciﬁc parameters in the decision-making process. 
This approach has the potential to better capture the whole beneﬁt of a population-
wide intervention which is particularly insightful in the elderly for whom mortality, 
disability and costs of health care are even more age-sensitive.
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IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL 
INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES:  
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OBJECTIVES: Cost-effectiveness analyses of behavioural health interventions typi-
cally use a dichotomous outcome criterion (success or failure). However, achieving 
behavioural change is a complex process in which several steps towards behavioural 
change are taken. Delayed behavioural effects may occur after an intervention or 
follow-up period ends, which can lead to underestimation of these interventions. As 
extending the follow-up period is often impeded by practical and ﬁnancial limitations, 
intermediate outcomes of behavioural change can be modelled into the cost-
 effectiveness ratio. The aim of this study is to model intermediate cognitive outcomes 
into a cost-effectiveness model of a behavioural intervention, comparing an intensive 
smoking cessation program (SST) with a less intensive smoking cessation program 
(LMIS) for COPD outpatients. METHODS: The cost-effectiveness analysis of an 
existing dataset was replicated by modelling the stages of change of the Transtheoreti-
cal Model of behavioural change. This stage-oriented model describes the readiness 
to change in qualitatively different, discrete stages; the ‘stages of change’. Costs were 
adjusted for the different stages of change participants were in. Probabilities to predict 
future behavioural change were obtained from the dataset and literature. Finally, a 
sensitivity analysis was performed. RESULTS: In the ﬁrst 12 months, the SST domi-
nated the LMIS in approximately 50% of the cases. By modelling the intermediate 
cognitive determinants to a future second year of follow-up, the SST dominated the 
LMIS in approximately 75% of all cases. CONCLUSIONS: This study showed that 
modelling of future behavioural change in cost-effectiveness analysis of a behavioural 
intervention led to a more favourable result. Further research should focus on collect-
ing longitudinal data of the cognitive determinants for different populations and 
outcome measures to be able to make a valid prediction of future behavioural change. 
Ultimately, this could have important consequences for health policy development in 
general and the adoption of behavioural interventions in particular.
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R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON 
OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL 
IMPLEMENTED IN MICROSOFT EXCEL AND R
Bischof M, Lim ME, Ferrusi IL, Burke N, Blackhouse G, Goeree R, Tarride JE
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OBJECTIVES: Comparison of the results of a decision analytic model developed in 
Microsoft Ofﬁce Excel® 2007 versus an implementation of the same model in R 
version 2.8.1 (www.R-project.org). The aim was to identify any difference in the per-
formance and validity between models implemented with the two software packages 
in terms of incremental cost-effectiveness ratio (ICER) estimates and probabilistic 
